SCHEMBL569327

SCHEMBL569327

CC(=O)N1CC(=O)c2ccc(F)cc21

nearest known ligand 0.60

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 3/20 0.60
HSD17B3 P37058 2/20 0.45
AVPR1A P37288 1/20 0.40
TGM2 P21980 1/20 0.37
TP53 P04637 1/20 0.36
KIF11 P52732 1/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
CA7 P43166 1/20 0.36
CA9 Q16790 1/20 0.36
KCNN4 O15554 1/20 0.35
KCNA3 P22001 1/20 0.35
BAZ2B Q9UIF8 1/20 0.35
AMPD2 Q01433 2/20 0.35
GFER P55789 1/20 0.35
CYP11B1 P15538 1/20 0.35
CYP11B2 P19099 1/20 0.35
LMNA P02545 1/20 0.34
TRIM24 O15164 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8959797 0.87 NOTUM (0.60) NOTUMHSD17B3AVPR1ATP53KIF11
SCHEMBL68600 0.80 NOTUM (0.60) NOTUMHSD17B3CA1CA2CA7
SCHEMBL28984695 0.80 NOTUM (0.60) NOTUMHSD17B3AVPR1AKCNN4KCNA3
SCHEMBL2005572 0.78 NOTUM (0.57) NOTUMHSD17B3CA1CA2CA7
SCHEMBL1048074 0.75 NOTUM (1.00) NOTUMHSD17B3KCNN4KCNA3LMNA
SCHEMBL30003296 0.75 NOTUM (1.00) NOTUMHSD17B3KCNN4KCNA3LMNA
SCHEMBL6218301 0.75 NOTUM (0.54) NOTUMHSD17B3CA1CA2CA7
SCHEMBL29187748 0.75 NOTUM (0.54) NOTUMCA1CA2CA7CA9
SCHEMBL5065354 0.72 PRKDC (0.50) NOTUM
SCHEMBL5712023 0.71 NOTUM (0.62) NOTUMHSD17B3TP53CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250091994-A1 RAS/RAF BINDING INHIBITOR COMPOUND NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY (JP) 2025-03-20 US disclosed
US-20140336208-A1 1,4,5,6-TETRAHYDRO-PYRIMIDIN-2-YLAMINE COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2014-11-13 US disclosed
US-8815881-B2 1,4,5,6-tetrahydro-pyrimidin-2-ylamine compounds HOFFMANN-LA ROCHE INC. (US) 2014-08-26 US disclosed
US-20120035195-A1 1,4,5,6-TETRAHYDRO-PYRIMIDIN-2-YLAMINE COMPOUNDS SIENA BIOTECH S.P.A., AN ITALIAN COMPANY (IT) 2012-02-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250091994-A1 RAS/RAF BINDING INHIBITOR COMPOUND BRAF, RAF1, NRAS NOTUM 4253/4885HSD17B3 4169/4885AVPR1A 3165/4885
US-20140336208-A1 1,4,5,6-TETRAHYDRO-PYRIMIDIN-2-YLAMINE COMPOUNDS BACE2, BACE1, PSEN2 NOTUM 913/4885HSD17B3 2076/4885AVPR1A 3029/4885
US-20120035195-A1 1,4,5,6-TETRAHYDRO-PYRIMIDIN-2-YLAMINE COMPOUNDS BACE2, BACE1, PSEN2 NOTUM 913/4885HSD17B3 2076/4885AVPR1A 3029/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.